Vator Securities: When genomics and proteomics converge, Immunovia will probably be snatched up
In addition to the usual comments you as the reader would expect from us in an update report post capital raise and presentation of long-term penetration target, we went further and asked ourselves: What is going to happen beyond the success of Immunovia’s first launch of IMMray PanCan-d? And here is what we believe is going to happen to proteomics-based (Immunovia) and genomics-based (e.g. Exact Sciences, Grail, Guardant) technologies in cancer diagnostics: · Proteomics eat Genomics for breakfast if the topic is VERY early detection · There will be no single-tech winners ·